bpc-157 news updates FDA panel votes to ease restrictions on an unregulated peptide FDA panel backs compounded BPC-157,

The clinics role is to move the conversation from cultural fascination into licensed medical review without pretending popularity establishes safety, eligibility, or guaranteed outcomes

Clements M, Heffernan M, Ward M, Hoey L, Doherty LC, Hack Mendes R, Clarke MM, Hughes CF, Love I, Murphy S, McDermott E, Grehan J, McCann A, McAnena LB, Strain JJ, Brennan L, McNulty H

Peptide therapeutics: Current status and future directions

Participants receiving the highest dose (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks results that exceeded those seen with currently approved agents at the time of publication

A second PCAC meeting before the end of February 2027 will review five additional peptides: GHK-Cu (injectable routes only